Status and phase
Conditions
Treatments
About
Phase III trial evaluating doravirine as an alternative to dolutegravir in treatment naïve people living with HIV-1 infection.
Full description
Phase III, multicenter, open-label, randomized, non-inferiority clinical trial which aims to assess the non-inferiority of doravirine in association with tenofovir and lamivudine, as compared to dolutegravir in association with tenofovir and lamivudine or emtricitabine.
This trial will be implemented in Brazil, Cambodia, Cameroon, Côte d'Ivoire, France and Mozambique.
Six hundred and ten patients will be enrolled and followed for 96 weeks after entry in the trial (=ART initiation).
Primary endpoint will assess virological efficacy at Week 48, measured by the proportion of subjects achieving HIV-1 RNA <50 copies/mL, in HIV-1 infected, treatment-naive subjects with pre-treatment viral load (HIV-1 RNA) ≥ 1,000 copies/mL.
Secondary endpoints are planned at W48 and W96.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Has ongoing (pulmonary or extra-pulmonary) tuberculosis (due to rifampin-doravirine drug-drug interaction)
Has any other history or current evidence of any condition, therapy, laboratory abnormality or other circumstance that might confound the results of the study or interfere with the subject's participation for the full duration of the study, such that it is not in the best interest of the subject to participate.
Is infected with HIV-2 or co-infected with HIV-1 and HIV-2
Has documented or known resistance to study drugs (in France and where national guidelines recommend screening for primary resistance before starting first-line ART), as defined below:
Have the following laboratory values at screening visit, within 30 days prior to the randomization:
Has participated in a study with an investigational compound/device within 30 days prior to signing informed consent or anticipates participating in such a study involving an investigational compound/device during the course of this study.
Has used systemic immunosuppressive therapy or immune modulators within 30 days prior to treatment in this study or is anticipated to need them during the course of the study
Requires or is anticipated to require any of the prohibited or contraindicated medications noted in the trial protocol.
Has significant hypersensitivity or other contraindication to any of the components of the study drugs.
Has a current (active) diagnosis of acute hepatitis, with AST (SGOT) and ALT (SGPT) >4.0 x ULN, due to any cause.
Is pregnant, breastfeeding, or expecting to conceive at any time during the study.
Has any condition which might, in the investigator's opinion, compromise the safety of treatment and/or patient's adherence to study procedure.
Is a person under guardianship or deprived of freedom by a judicial or administrative decision.
Primary purpose
Allocation
Interventional model
Masking
610 participants in 2 patient groups
Loading...
Central trial contact
Olivier Pr MARCY; Anthony L'HOSTELLIER
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal